NCT02558933View on ClinicalTrials.gov

Epigallocatechin Gallate (EGCG) to Improve Cognitive Performance in Foetal Alcohol Syndrome (FAS) Children

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

September 30, 2017

Conditions
Fetal Alcohol Syndrome (FAS)
Interventions
DIETARY_SUPPLEMENT

Epigallocatechin gallate

Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.

Trial Locations (1)

08003

Parc de Salut Mar, Barcelona

All Listed Sponsors
collaborator

Parc de Salut Mar

OTHER

lead

Fundacion Clinic per a la Recerca Biomédica

OTHER

NCT02558933 - Epigallocatechin Gallate (EGCG) to Improve Cognitive Performance in Foetal Alcohol Syndrome (FAS) Children | Biotech Hunter | Biotech Hunter